Declan LeBaron, an 8-year-old Philadelphia Eagles super fan, told Fox News Digital how he felt when he was surprised by ...

Gout can occur in the hip joint rarely. In gout, uric acid crystals build up in the joints. There can be sudden, severe pain ...

Juvenile Arthritis Research are launching the UK’s first ever Juvenile Arthritis Month in March. It will be known as JAMJAR (Juvenile Arthritis Month by Juvenile Arthritis Research) and will raise ...

Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and ...

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra, developed by South ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...